KBC Group’s Kite Pharma, Inc. KITE Stock Holding History

KBC Group’s Portfolio KITE Stock Details KITE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-4,362	Closed	-$452K	–	1302
2017 Q2	$452K	Buy	+4,362	New	+$356K	﹤0.01%	974

Other funds holding KITE

Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCSAM

Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

KBC Group's KITE Position: Q3 2017 in Review

KBC Group sold out of Kite Pharma, Inc. (KITE) in Q3 2017, closing a stake of 4,362 shares — an estimated $452K sold.

KBC Group first reported a position in KITE in Q2 2017 and held it in 1 quarter. The position peaked at $452K in Q2 2017. 244 funds tracked by Wall St. Rank hold KITE as of Q3 2017.

KBC Group reported no remaining Kite Pharma, Inc. position as of Q3 2017 after selling out during the quarter.
KBC Group sold 4,362 Kite Pharma, Inc. shares in Q3 2017, an estimated $452K.
KBC Group first reported a position in Kite Pharma, Inc. in Q2 2017 and held it in 1 quarter.
KBC Group's Kite Pharma, Inc. position peaked at $452K in Q2 2017.
244 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q3 2017.

Based on KBC Group's 13F filing for Q3 2017, filed 13 Nov 2017.